Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLI1 | Q01543 | 5/20 | 0.75 |
| ▸ | EWSR1 | Q01844 | 5/20 | 0.75 |
| ▸ | ERG | P11308 | 1/20 | 0.75 |
| ▸ | ETV1 | P50549 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.70 |
| ▸ | MMP8 | P22894 | 9/20 | 0.57 |
| ▸ | MMP9 | P14780 | 8/20 | 0.57 |
| ▸ | MMP2 | P08253 | 8/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13253318 | 0.90 | FLI1 (0.77) | FLI1EWSR1ERGETV1ALDH1A1 | |
| SCHEMBL17679858 | 0.89 | FLI1 (0.75) | FLI1EWSR1ERGETV1ALDH1A1 | |
| SCHEMBL17679857 | 0.89 | FLI1 (0.75) | FLI1EWSR1ERGETV1ALDH1A1 | |
| SCHEMBL13253333 | 0.89 | FLI1 (0.75) | FLI1EWSR1ERGETV1ALDH1A1 | |
| SCHEMBL13253323 | 0.88 | ALDH1A1 (0.84) | FLI1EWSR1ERGETV1ALDH1A1 | |
| SCHEMBL29810788 | 0.88 | FLI1 (0.73) | FLI1EWSR1ERGETV1ALDH1A1 | |
| SCHEMBL17679855 | 0.88 | FLI1 (0.73) | FLI1EWSR1ERGETV1ALDH1A1 | |
| SCHEMBL13253331 | 0.88 | FLI1 (0.73) | FLI1EWSR1ERGETV1ALDH1A1 | |
| SCHEMBL17679856 | 0.88 | FLI1 (0.73) | FLI1EWSR1ERGETV1ALDH1A1 | |
| SCHEMBL17669239 | 0.88 | FLI1 (0.73) | FLI1EWSR1ERGETV1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9987251-B2 | Indolinone compounds and uses thereof | Oncternal Therapeutics, Inc. (US) | 2018-06-05 | — | — | US | disclosed |
| US-9895352-B2 | Indolinone compounds and uses thereof | Oncternal Therapeutics, Inc. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20180028495-A1 | USES OF INDOLINONE COMPOUNDS | GEORGETOWN UNIVERSITY | 2018-02-01 | — | — | US | disclosed |
| US-9758481-B2 | Targeting of EWS-FLI1 as anti-tumor therapy | GEORGETOWN UNIVERSITY (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758481-B2 | Targeting of EWS-FLI1 as anti-tumor therapy | GEORGETOWN UNIVERSITY (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758481-B2 | Targeting of EWS-FLI1 as anti-tumor therapy | GEORGETOWN UNIVERSITY (US) | 2017-09-12 | — | — | US | disclosed |
| US-9714222-B2 | Methods and compositions for treating Ewings sarcoma family of tumors | GEORGETOWN UNIVERSITY (US) | 2017-07-25 | — | — | US | disclosed |
| US-9714222-B2 | Methods and compositions for treating Ewings sarcoma family of tumors | GEORGETOWN UNIVERSITY (US) | 2017-07-25 | — | — | US | disclosed |
| US-20170157089-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | NIH - DEITR | 2017-06-08 | — | — | US | disclosed |
| US-20170157089-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | NIH - DEITR | 2017-06-08 | — | — | US | disclosed |
| US-20100167994-A1 | TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY | GEORGETOWN UNIVERSITY (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100167994-A1 | TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY | GEORGETOWN UNIVERSITY (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100167994-A1 | TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY | GEORGETOWN UNIVERSITY (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100035814-A1 | N-Terminal Pegylated Prolactin Receptor Molecules | NOVO NORDISK A/S (DK) | 2010-02-11 | — | — | US | disclosed |
| US-20100004179-A1 | TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY | GEORGETOWN UNIVERSITY | 2010-01-07 | — | — | US | disclosed |
| US-20100004179-A1 | TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY | GEORGETOWN UNIVERSITY | 2010-01-07 | — | — | US | disclosed |
| US-20100004179-A1 | TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY | GEORGETOWN UNIVERSITY | 2010-01-07 | — | — | US | disclosed |
| EP-2086588-A2 | N-TERMINAL PEGYLATED PROLACTIN RECEPTOR MOLECULES | NOVO NORDISK A/S (DK) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008083326-A2 | TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY | GEORGETOWN UNIVERSITY (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008055972-A2 | N-TERMINAL PEGYLATED PROLACTIN RECEPTOR MOLECULES | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004179-A1 | TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY | EWSR1, FLI1, PELI1 | FLI1 2/4885EWSR1 1/4885ERG 47/4885 |
| US-20180028495-A1 | USES OF INDOLINONE COMPOUNDS | MCL1, BCL3, BCL9 | FLI1 8/4885EWSR1 823/4885ERG 311/4885 |
| US-20170157089-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | MGMT, TP53, KRAS | FLI1 527/4885EWSR1 17/4885ERG 530/4885 |
| US-20100035814-A1 | N-Terminal Pegylated Prolactin Receptor Molecules | PRLHR, GHRHR, TRHR | FLI1 4549/4885EWSR1 2102/4885ERG 3416/4885 |
| US-20100167994-A1 | TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY | EWSR1, FLI1, PELI1 | FLI1 2/4885EWSR1 1/4885ERG 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.